skip to Main Content

Dr. Wolpin on the CCGA Study of Blood-Based Testing for Early Detection of GI Cancers

Dr. Wolpin on the CCGA Study of Blood-Based Testing for Early Detection of GI Cancers
Brian M. Wolpin, MD, MPH, associate professor of medicine, Harvard Medical School, director, Gastrointestinal (GI) Cancer Center, co-director, Pancreas and Billary Tumor Center, Robert T. and Judith B. Hale Chair in Pancreatic Cancer, Dana-Farber Cancer Institute, discusses the GI subgroup findings of the Circulating Cell-Free Genome Atlas (CCGA) study (NCT02889978). [/subhead}

The study evaluated the efficacy of using a DNA methylation–based circulating cell-free DNA (cfDNA) assay to detect cancers specific to regions of the GI tract. Watch here . . .


Back To Top